S A Zimmerman

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura
    S A Zimmerman
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 57:131-8. 1998
  2. ncbi request reprint Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Duke University Medical Center, PO Box 2916, Durham, NC 27710, USA
    Blood 103:2039-45. 2004
  3. ncbi request reprint Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations
    S A Zimmerman
    Paediatric Sickle Cell Program and the Division of Paediatric Hematology Oncology, Department of Paediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Lab Haematol 22:145-50. 2000
  4. ncbi request reprint Hemoglobin S/O(Arab): thirteen new cases and review of the literature
    S A Zimmerman
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 60:279-84. 1999
  5. ncbi request reprint Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease
    S A Zimmerman
    Duke UNC Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 59:267-72. 1998
  6. ncbi request reprint Subclinical parvovirus B19 infection in children with sickle cell anemia
    Sherri A Zimmerman
    Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 25:387-9. 2003
  7. ncbi request reprint An infant with homozygous hemoglobin D-Iran
    C D Thornburg
    Pediatric Residency Training Program, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 23:67-8. 2001
  8. ncbi request reprint Hydroxyurea therapy for pediatric patients with hemoglobin SC disease
    M K Miller
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 23:306-8. 2001
  9. ncbi request reprint Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
    R E Ware
    Duke Pediatric Sickle Cell Program and the Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Blood 94:3022-6. 1999
  10. ncbi request reprint Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting
    D Martincic
    Department of Pediatrics, Pathology, and Medicine, Vanderbilt University, Nashville, TN, USA
    Blood 92:3309-17. 1998

Research Grants

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura
    S A Zimmerman
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 57:131-8. 1998
    ..We conclude that anti-D has no demonstrable in vitro or in vivo effects on lymphocyte enumeration or function, and therefore likely is effective in the treatment of ITP primarily through RES blockade...
  2. ncbi request reprint Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Duke University Medical Center, PO Box 2916, Durham, NC 27710, USA
    Blood 103:2039-45. 2004
    ..Long-term hydroxyurea therapy at MTD is well tolerated by pediatric patients with SCD and has sustained hematologic efficacy with apparent long-term safety...
  3. ncbi request reprint Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations
    S A Zimmerman
    Paediatric Sickle Cell Program and the Division of Paediatric Hematology Oncology, Department of Paediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Lab Haematol 22:145-50. 2000
    ..Clinical complications of splenomegaly include acute splenic sequestration in younger patients and hypersplenism with chronic thrombocytopenia in older children...
  4. ncbi request reprint Hemoglobin S/O(Arab): thirteen new cases and review of the literature
    S A Zimmerman
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 60:279-84. 1999
    ..We conclude that Hb S/O(Arab) disease is a severe sickling hemoglobinopathy with laboratory and clinical manifestations similar to those of homozygous sickle cell anemia...
  5. ncbi request reprint Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease
    S A Zimmerman
    Duke UNC Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Hematol 59:267-72. 1998
    ..Although each of these mutations is relatively common in patients with SCD, neither is independently associated with an increased risk of developing stroke or AVN...
  6. ncbi request reprint Subclinical parvovirus B19 infection in children with sickle cell anemia
    Sherri A Zimmerman
    Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 25:387-9. 2003
    ..To investigate the prevalence and clinical consequences of previous parvovirus B19 exposure in a large cohort of pediatric patients with sickle cell anemia (SCA)...
  7. ncbi request reprint An infant with homozygous hemoglobin D-Iran
    C D Thornburg
    Pediatric Residency Training Program, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 23:67-8. 2001
    ....
  8. ncbi request reprint Hydroxyurea therapy for pediatric patients with hemoglobin SC disease
    M K Miller
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 23:306-8. 2001
    ..All patients improved clinically. Our findings demonstrate that HU therapy benefits pediatric patients with severe HbSC disease, although larger clinical trials of HU therapy in HbSC disease are warranted...
  9. ncbi request reprint Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease
    R E Ware
    Duke Pediatric Sickle Cell Program and the Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Blood 94:3022-6. 1999
    ..Phlebotomy is well-tolerated and significantly reduces iron overload. Modifications in HU therapy to raise HbF more rapidly might increase protection against stroke recurrence...
  10. ncbi request reprint Identification of mutations and polymorphisms in the factor XI genes of an African American family by dideoxyfingerprinting
    D Martincic
    Department of Pediatrics, Pathology, and Medicine, Vanderbilt University, Nashville, TN, USA
    Blood 92:3309-17. 1998
    ..4%, 19%, and 18%, respectively. This suggests that there is considerable genetic heterogeneity in the factor XI gene...
  11. ncbi request reprint Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia
    R G Passon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 23:448-51. 2001
    ..The effects of UGT1A promoter polymorphisms on serum bilirubin levels and symptomatic gallstone formation were studied in a cohort of children with sickle cell anemia (SCA)...
  12. ncbi request reprint Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus
    E A Higginbotham
    Medicine-Pediatric Residency Training Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Rheumatol 28:370-2. 2001
    ..Inherited thrombophilic DNA mutations may contribute to the hypercoagulability observed in patients with acquired thrombophilic conditions such as APS and systemic lupus erythematosus...
  13. ncbi request reprint Genitourinary complications of sickle cell disease
    D Bruno
    Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Urol 166:803-11. 2001
    ..New forms of therapy for sickle cell disease, such as hydroxyurea, may prevent these complications in the future...
  14. ncbi request reprint UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia
    Matthew M Heeney
    Pediatric Sickle Cell Program and Division of Pediatric Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
    J Lab Clin Med 141:279-82. 2003
    ..UGT1A promoter polymorphisms may therefore influence the ability of hydroxyurea to prevent gallstone formation in patients with SCA...
  15. ncbi request reprint Acute parvovirus B19 infection mimicking congenital dyserythropoietic anemia
    Shannon L Carpenter
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr Hematol Oncol 26:133-5. 2004
    ..This case expands the spectrum of hematologic disease associated with acute parvovirus infection...
  16. ncbi request reprint Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy
    Russell E Ware
    Duke Pediatric Sickle Cell Program, Division of Hematology Oncology, Duke University Medical Center, Durham, North Carolina, USA
    J Pediatr 145:346-52. 2004
    ..Transfusions prevent secondary stroke in children with sickle cell anemia (SCA) but also cause iron overload. Alternatives for stroke prophylaxis with effective therapy to reduce iron burden are needed...
  17. ncbi request reprint Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease
    Virginia L Harrod
    Department of Hematology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Exp Hematol 35:179-83. 2007
    ..Analysis of these cell populations allows quantitative measurement of splenic filtrative function and possible chromosomal damage...
  18. ncbi request reprint Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
    Sherri A Zimmerman
    Duke Pediatric Sickle Cell Program, and Division of Pediatric Hematology Oncology, Duke University Medical Center, Durham, NC, USA
    Blood 110:1043-7. 2007
    ..A multicenter trial is warranted to determine the efficacy of hydroxyurea for the management of increased TCD values, and ultimately for primary stroke prevention in children with SCA...
  19. ncbi request reprint Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency
    Matthew M Heeney
    Division of Hematology Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Pediatr 143:662-5. 2003
    ..Routine screening of immunoglobulins is suggested for children with chronic or recurrent immune thrombocytopenic purpura and autoimmune hemolytic anemia...
  20. ncbi request reprint Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease
    Ulrike M Reiss
    Department of Hematology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Am J Hematol 82:740-3. 2007
    ..Hydroyxurea provides a novel and useful therapeutic approach to reduce hyperviscosity from secondary erythrocytosis in patients with CCHD, while preserving oxygen carrying capacity and avoiding iron depletion by phlebotomy...

Research Grants1

  1. ETIOLOGY OF STROKE IN CHILDREN WITH SICKLE CELL DISEASE
    Sherri Zimmerman; Fiscal Year: 2004
    ..Based on this fact-finding study, I will design a hypothesis-driven therapeutic clinical trial for children at highest risk of developing stroke. ..